Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Proteomic and Mechanistic Analysis of Spironolactone in Patients at Risk for HF
João Pedro Ferreira, Job A.J. Verdonschot, Ping Wang, et al.
JACC Heart Failure (2021) Vol. 9, Iss. 4, pp. 268-277
Open Access | Times Cited: 62

Showing 1-25 of 62 citing articles:

Inflammatory pathways in heart failure with preserved left ventricular ejection fraction: implications for future interventions
Nicola Riccardo Pugliese, Pierpaolo Pellicori, Francesco Filidei, et al.
Cardiovascular Research (2022) Vol. 118, Iss. 18, pp. 3536-3555
Open Access | Times Cited: 73
Small Extracellular Vesicles From Infarcted and Failing Heart Accelerate Tumor Growth
Tal Caller, Itai Rotem, Olga Shaihov–Teper, et al.
Circulation (2024) Vol. 149, Iss. 22, pp. 1729-1748
Closed Access | Times Cited: 17
Nonsteroidal mineralocorticoid receptor antagonism for cardiovascular and renal disorders − New perspectives for combination therapy
Peter Kolkhof, Amer Joseph, Ulrich Kintscher
Pharmacological Research (2021) Vol. 172, pp. 105859-105859
Open Access | Times Cited: 56
Cardiac remodelling – Part 1: From cells and tissues to circulating biomarkers. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology
Arantxa González, Mark Richards, Rudolf A. de Boer, et al.
European Journal of Heart Failure (2022) Vol. 24, Iss. 6, pp. 927-943
Open Access | Times Cited: 50
Cardiac Fibrosis in heart failure: Focus on non-invasive diagnosis and emerging therapeutic strategies
Susana Ravassa, Begoña López, Thomas A. Treibel, et al.
Molecular Aspects of Medicine (2023) Vol. 93, pp. 101194-101194
Open Access | Times Cited: 36
High-sensitivity C-reactive protein in heart failure with preserved ejection fraction: Findings from TOPCAT
João Pedro Ferreira, Brian Claggett, Jiankang Liu, et al.
International Journal of Cardiology (2024) Vol. 402, pp. 131818-131818
Closed Access | Times Cited: 13
Methods and clinical biomarker discovery for targeted proteomics using Olink technology
Han Wang, Tian Zhao, Jingjing Zeng, et al.
PROTEOMICS - CLINICAL APPLICATIONS (2024) Vol. 18, Iss. 5
Closed Access | Times Cited: 8
Structural and molecular determinants of mineralocorticoid receptor signalling
Claudia Großmann, Brian Almeida‐Prieto, Alexander Nolze, et al.
British Journal of Pharmacology (2021) Vol. 179, Iss. 13, pp. 3103-3118
Open Access | Times Cited: 45
Using Artificial Intelligence to Better Predict and Develop Biomarkers
Sam A. Michelhaugh, James L. Januzzi
Heart Failure Clinics (2022) Vol. 18, Iss. 2, pp. 275-285
Closed Access | Times Cited: 34
Mineralocorticoid receptor antagonists with sodium–glucose co-transporter-2 inhibitors in heart failure: a meta-analysis
Mainak Banerjee, Indira Maisnam, Rimesh Pal, et al.
European Heart Journal (2023) Vol. 44, Iss. 37, pp. 3686-3696
Open Access | Times Cited: 21
Mineralocorticoid receptor antagonism in diabetes reduces albuminuria by preserving the glomerular endothelial glycocalyx
Michael Crompton, Joanne Ferguson, Raina D. Ramnath, et al.
JCI Insight (2023) Vol. 8, Iss. 5
Open Access | Times Cited: 19
Mineralocorticoid receptor promotes cardiac macrophage inflammaging
Daniela Fraccarollo, Robert Geffers, Paolo Galuppo, et al.
Basic Research in Cardiology (2024) Vol. 119, Iss. 2, pp. 243-260
Open Access | Times Cited: 6
Differentiation between emerging non-steroidal and established steroidal mineralocorticoid receptor antagonists: head-to-head comparisons of pharmacological and clinical characteristics
Jonatan Barrera‐Chimal, Peter Kolkhof, Ixchel Lima‐Posada, et al.
Expert Opinion on Investigational Drugs (2021) Vol. 30, Iss. 11, pp. 1141-1157
Open Access | Times Cited: 37
Aldosterone and cardiovascular diseases
Wasita Warachit Parksook, Gordon H. Williams
Cardiovascular Research (2022) Vol. 119, Iss. 1, pp. 28-44
Open Access | Times Cited: 27
Sodium zirconium cyclosilicate for MRAs optimization in HFrEF: lessons learned from the REALIZE-K trial
Luca Monzo, Francesca Musella, Nicolas Girerd, et al.
Heart Failure Reviews (2025)
Closed Access
Matrix Metalloproteinases in Cardioembolic Stroke: From Background to Complications
Anna Wysocka, Jacek Szczygielski, Marta Kopańska, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 4, pp. 3628-3628
Open Access | Times Cited: 12
Improving diagnosis and risk stratification across the ejection fraction spectrum: the Maastricht Cardiomyopathy registry
Michiel T.H.M. Henkens, Jerremy Weerts, Job A.J. Verdonschot, et al.
ESC Heart Failure (2022) Vol. 9, Iss. 2, pp. 1463-1470
Open Access | Times Cited: 15
Proteomic Analysis of Effects of Spironolactone in Heart Failure With Preserved Ejection Fraction
Ali Javaheri, Ahmed Diab, Lei Zhao, et al.
Circulation Heart Failure (2022) Vol. 15, Iss. 9
Open Access | Times Cited: 15
Spironolactone effect on circulating procollagen type I carboxy-terminal propeptide: Pooled analysis of three randomized trials
João Pedro Ferreira, John G.F. Cleland, Nicolas Girerd, et al.
International Journal of Cardiology (2023) Vol. 377, pp. 86-88
Open Access | Times Cited: 8
Effects of empagliflozin on collagen biomarkers in patients with heart failure: Findings from the EMPEROR trials
João Pedro Ferreira, Javed Butler, Stefan D. Anker, et al.
European Journal of Heart Failure (2023) Vol. 26, Iss. 2, pp. 274-284
Open Access | Times Cited: 8
Outpatient diuretic intensification as endpoint in heart failure with preserved ejection fraction trials: an analysis from TOPCAT
João Pedro Ferreira, Jiankang Liu, Brian Claggett, et al.
European Journal of Heart Failure (2021) Vol. 24, Iss. 2, pp. 378-384
Open Access | Times Cited: 19
Cardiomyocyte PANX1 Controls Glycolysis and Neutrophil Recruitment in Hypertrophy
Caitlin M. Pavelec, A. P. Young, Hannah L. Luviano, et al.
Circulation Research (2024) Vol. 135, Iss. 4, pp. 503-517
Closed Access | Times Cited: 2
Transforming personalized chronic pain management with artificial intelligence: A commentary on the current landscape and future directions
Stefano Casarin, Nele A. Haelterman, Keren Machol
Experimental Neurology (2024) Vol. 382, pp. 114980-114980
Open Access | Times Cited: 2
Using Artificial Intelligence to Better Predict and Develop Biomarkers
Sam A. Michelhaugh, James L. Januzzi
Clinics in Laboratory Medicine (2023) Vol. 43, Iss. 1, pp. 99-114
Closed Access | Times Cited: 6
Influence of ejection fraction on biomarker expression and response to spironolactone in people at risk of heart failure: findings from the HOMAGE trial
João Pedro Ferreira, Job A.J. Verdonschot, Nicolas Girerd, et al.
European Journal of Heart Failure (2022) Vol. 24, Iss. 5, pp. 771-778
Open Access | Times Cited: 10
Page 1 - Next Page

Scroll to top